B. Glick, E. Lain, T. Lin, and R. Israel, “Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast)”, J of Skin, vol. 3, p. S30, Nov. 2019.